Table 1.
Patient background, time‐course of admission and assessment prior to tocilizumab administration
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Demographic data and medical background | |||||
| Age (y) | 53 | 74 | 71 | 70 | 46 |
| Gender | Male | Male | Male | Male | Male |
| Weight (kg) | 70 | 90 | 68 | 72 | 86 |
| BMI (kg/m2) | 25.1 | 27.2 | 23.0 | 26.5 | 32.8 |
| Smoker | No | No | No | No | No |
| Ethnicity | Chinese | Caucasian | Caucasian | Indian | Filipino |
| Coexisting chronic diseases | Hypertension, dyslipidemia | Type II diabetes mellitus, hypertension | Dyslipidemia, aortic valve replacement, lacunar stroke | Type II diabetes mellitus | Asthma, obesity |
| Regular medications | Rosuvastatin, telmisartan | Allopurinol, aspirin, gliclazide MR, irbesartan, metformin, rosuvastatin | Aspirin, pantoprazole, ramipril, rosuvastatin, warfarin | Metformin | Salbutamol as‐needed |
| Time‐course from day of symptom onset | |||||
| Event | Days later | Days later | Days later | Days later | Days later |
| SARS‐CoV2 swab + ve | 2 | 3 | 1 | 2 | 0 |
| Hospital admission | 11 | 6 | 13 | 2 | 3 |
| O2 requirement started | 11 | 9 | 13 | 3 | 5 |
| ICU admission | 11 | 14 | 13 | 3 | 6 |
| Intubation | 11 | (Not intubated) | (Not intubated) | 3 | 7 |
| TCZ administration | 11 | 14 | 13 | 9 | 9 |
| Assessment prior to TCZ | |||||
| PF ratio (mm Hg) | 124 | 198 | 93 | 112 | 69 |
| SOFA score | 6 | 2 | 2 | 7 | 14 |
| H‐score | Insufficient data | Insufficient data | Insufficient data | 151 | 132 |
| Infection screen | |||||
| When tested vs TCZ | 4 d prior | 2 h after | 3 h prior | 11 h prior | Not tested |
| QuantiFERON Gold | Indeterminate | Indeterminate | Indeterminate | Not tested | Not tested |
| Hepatitis B serology | Vaccinated | Negative | Negative | Negative | Not tested |
| HIV serology | Negative | Negative | Negative | Negative | Not tested |
Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; ICU, intensive care unit; MR, modified release; O2, oxygen; PF ratio, ratio of partial pressure of oxygen in arterial blood to fraction of inspired oxygen; SARS‐CoV2, severe acute respiratory syndrome‐coronavirus 2; SOFA, sequential organ failure assessment; TCZ, tocilizumab.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.